Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market ...

Rigel Reports Second Quarter 2026 Financial Results

Rigel reported net income of $17.3 million, or $0.93 basic and $0.88 diluted per share, compared to $59.6 million, or $3.33 basic and $3.28 diluted per share, for the same period of 2025. As noted ...
CNBC

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Monday - Friday, 2:00 - 3:00 PM ET In this article It's been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for ...

Rigel projects $285M-$295M 2026 total revenue while preparing mid-august VEPPANU launch

Schorno said 2026 guidance was increased and tightened to “approximately $285 million to $295 million,” with “approximately $255 million to $265 million in net product sales, excluding VEPPANU and ...
Yahoo Finance

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Motley Fool

3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

On Feb. 18, 2021, Eli Lilly coughed up $125 million upfront to license R552 from Rigel Pharmaceuticals. This is a small molecule drug designed to inhibit RIPK1, a protein that regulates which cells ...

Arvinas expects cash runway into the second half of 2028 as ARV-102 PSP trials shift to 2027

He added, “we completed an out-licensing of VEPPANU to Rigel Pharmaceuticals” and “made the strategic decision that our KRAS G12D program, ARV-806, will only move forward in the hands of a partner,” ...